Structured population data were available for 5 of 5 supporting studies. 4 studies described participants with type 2 diabetes. 4 studies described adult participants.

1 supporting study does not have a displayable topic-matched quantitative effect.

Evidence uses heterogeneous comparison contexts: active_comparator, placebo.

Placebo

Core clinician-reference fields are available or not applicable.

Participants received empagliflozin for 4 weeks followed by a placebo for 4 weeks.

Empagliflozin

Adults with HNF1A-MODY treated with at least one glucose-lowering drug were randomized to be treated with empagliflozin 25 mg for 4 weeks followed by a 2-week washout period and then received placebo for 4 weeks or the opposite sequence.

Participants received placebo for 4 weeks after the empagliflozin period.

Participants received placebo for 4 weeks or the opposite sequence.

Empagliflozin improves glycemic control in HNF1A-MODY

Patients receiving empagliflozin 10 mg as add-on treatment.

Empagliflozin 10 mg

Participants were randomised 1:1:1 to empagliflozin 10 mg, empagliflozin 25 mg, or placebo.

Patients receiving empagliflozin 25 mg as add-on treatment.

Empagliflozin 25 mg

Patients receiving placebo as add-on treatment.

Empagliflozin improves glycemic control in type 2 diabetes patients

Available source content was suppressed because validation identified a conflict.

Patients received empagliflozin 10 mg/day.

Empagliflozin 10 mg/day

Patients with T2DM and elevated left ventricular E / E ' ratio were enrolled and randomized 1:1 to receive empagliflozin 10 mg/day versus placebo.

Authoritative quality diagnostic: invalid or missing value.

Empagliflozin improves heart function in type 2 diabetes patients

Glimepiride group

Patients received empagliflozin for 12 weeks after initial treatment.

Empagliflozin group

The empagliflozin group ( n = 33) showed no significant differences in ΔFMDs.

Patients received glimepiride for 12 weeks after initial treatment.

The glimepiride group ( n = 30) showed no significant differences in ΔFMDs.

Authoritative quality diagnostic: invalid or missing unit.

Empagliflozin reduces body fluid volume in type 2 diabetes patients

Drug-naïve adolescents receiving empagliflozin for 26 weeks.

Drug-naïve adolescents and those not on active therapy received the SGLT2 inhibitor empagliflozin for 26 weeks.

Drug-naïve adolescents receiving linagliptin for 26 weeks.

Linagliptin 5 mg

Drug-naïve adolescents and those not on active therapy received the DPP-4 inhibitor linagliptin for 26 weeks.

Drug-naïve adolescents receiving placebo for 26 weeks.

Participants from DINAMO + DINAMO MONO (hereinafter referred to as adolescents) were randomized to placebo (n = 9).

Young adults receiving empagliflozin for 24 weeks.

Empagliflozin 10 mg or 25 mg

Young adults were randomized to empagliflozin 10 or 25 mg for 24 weeks.

Young adults receiving sitagliptin for 24 weeks.

Sitagliptin 100 mg

Young adults were randomized to sitagliptin 100 mg for 24 weeks.

Young adults receiving placebo for 24 weeks.

Young adults were randomized to placebo for 24 weeks.

Empagliflozin × Body weight

Available supporting studies

Empagliflozin improves glycemic control in HNF1A-MODY

Empagliflozin improves glycemic control in type 2 diabetes patients

Empagliflozin improves heart function in type 2 diabetes patients

Empagliflozin reduces body fluid volume in type 2 diabetes patients

Empagliflozin reduces HbA1c in youth with type 2 diabetes